What is Upadacitinib?
Upadacitinib is a disease-modifying antirheumatic medication (DMARD) that is taken orally to suppress the activity of Janus kinase (JAK)1 and to reduce the progression of rheumatoid arthritis. Peripheral joints are affected by rheumatoid arthritis, a chronic autoimmune inflammatory disease. It is typified by autoantibody production, bone and cartilage degradation, synovial inflammation and hyperplasia, and co-morbidities. Even with a wide range of therapeutic agents at their disposal, up to 40% of patients still do not react to existing treatments, including biological therapies. Although the disease’s aetiology is mostly unknown, research has shown that JAK has a role in immune-mediated diseases. This finding has led to the development of JAK as a therapeutic target for rheumatoid arthritis.
Upadacitinib and Filgotinib, two more selective JAK1 inhibitors, were created in order to lessen dose-related toxicity (which has been observed with certain pan-JAK inhibitors) without appreciably compromising efficacy. For the treatment of individuals with moderately to severely active rheumatoid arthritis who have not responded well to methotrexate or have developed an intolerance to it, the FDA authorised Upadacitinib in August 2019. It can be used as monotherapy or in conjunction with methotrexate; the European Commission authorised it in December 2019. RINVOQTM is the brand name under which upadacitinib is sold for oral use. A number of clinical trials are presently being conducted to evaluate its efficacy as a treatment for several inflammatory conditions, including psoriatic arthritis, ankylosing spondylitis, ulcerative colitis, and atopic dermatitis.
Download GMP-Certified API Product List
MedicaPharma is an EU-based supplier of GMP-certified APIs that serves leading healthcare institutions and research organizations. Click here to download our complete API product list.
Get your requested raw materials quotation
Table of Contents
Mechanism of Action
The main way that Upadacitinib works as a medication is by blocking Janus kinases, especially JAK1. These enzymes are vital for the transmission of signals related to inflammation and immunological responses. Upadacitinib interferes with the signalling cascade that generates pro-inflammatory cytokines by inhibiting JAK1. This modulation relieves the symptoms of inflammatory disorders such as psoriatic arthritis, rheumatoid arthritis, atopic dermatitis, and ulcerative colitis (UC) by reducing inflammation and regulating immunological responses.
Get your requested raw materials quotation
Upadacitinib’s Medical Uses
Upadacitinib was first licensed to treat rheumatoid arthritis, but it has now shown efficacy and safety characteristics that have allowed for its approval to be used to treat additional inflammatory diseases. These extend its therapeutic applications beyond its original indication and include psoriatic arthritis and atopic dermatitis. It is especially noteworthy for how well it works to treat the symptoms of ulcerative colitis, a kind of inflammatory bowel disease (IBD). Upadacitinib represents a significant development in the treatment of ulcerative colitis (UC), offering new choices for patients who do not respond well to conventional medications due to its capacity to directly target and control immune responses in the gut.
In conclusion, Upadacitinib API is a state-of-the-art therapeutic strategy for the treatment of inflammatory diseases and immunology. Patients with a variety of chronic inflammatory disorders can benefit from a targeted strategy to reduce symptoms and enhance their quality of life by selectively suppressing JAK1.
Are there any known adverse reactions or side effects of Upadacitinib?
Common adverse reactions
The most common side effects (≥1% of patients) listed in the prescribing information include:
- Upper respiratory tract infections (common cold, sinus infections)
- Nausea
- Cough
- Fever
Serious adverse reactions
The serious adverse reactions listed in the prescribing information include:
- Serious infections
- Lymphoma and other malignancies
- Thrombosis
Upadacitinib Price Comparison
When comparing the price of Upadacitinib with other UC medications, one can determine the drug’s competitive standing in the market. Due to its novel approach and focused mode of action, Upadacitinib was initially more expensive; but, over time, its ability to cause and sustain remission might make it more cost-effective. Reductions in hospital stays and procedures, as well as enhanced quality of life linked to efficient illness treatment, are frequently taken into account in cost-effectiveness evaluations.
Buy Upadacitinib From MedicaPharma
MedicaPharma is your trusted source of top-quality Upadacitinib manufactured in accordance with Good Manufacturing Practices (GMP).
Upadacitinib is expanding quickly in both the domestic and international markets, and we have received widespread recognition and substantial returns. As a distributor, we are able to guarantee that the newest production equipment, in addition to senior engineers with extensive training and qualified technical teams, follow stringent process requirements and international guidelines.
MedicaPharma is a reputable API distributor that supplies global pharmaceutical customers, including hospitals, compounding pharmacies, and universities. We deliver all products according to Good Distribution Practices (GDP) regulations.
We support you with an extensive range of niche APIs produced by GMP-certified manufacturers worldwide.
- Supply according to GDP regulations
- A global network of over 400 GMP Manufacturers
- Pharmaceutical chemicals (GMP) and more
Get a Fast and Easy GMP-Certified API Quote
Focus on your compounding pharmacy business and let MedicaPharma take care of your APIs. Obtaining a quote is easy
